首页> 外文期刊>European journal of drug metabolism and pharmacokinetics >Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers.
【24h】

Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers.

机译:在健康志愿者中单次口服后,α-甲基多巴正常和薄膜片剂的生物利用度比较。

获取原文
获取原文并翻译 | 示例
           

摘要

In a single dose, randomized, cross-over study, with one week of wash-out period, the relative bioavailability of Dopegyt tablets containing 250 mg alpha-methyldopa (AMD) and Presinol film tablets with identical active ingredient content was examined in 24 healthy volunteers. Since technologically two completely different preparations (a film-tablet and a non-film-tablet) having significantly different in vitro dissolution were to be compared, both preparations were compared to a third one, AMD solution (Dopegyt solution) with 250 mg/50 ml concentration. Plasma concentrations of the drug were measured for 24 hours post-dose, applying HPLC with fluorometric detection. Pharmacokinetic parameters calculated from individual data (AUC0-infinity, AUC0-t, Cmax, Cmax/AUC0-infinity, t(max)) were evaluated statistically. Wilcoxon's nonparametric test and the four-way variance analysis could not detect any significant difference at the usual a=95% probability level in these pharmacokinetic parameters of the two tablet preparations. For AUC0-infinity at the 90% probability level, the confidence interval was 0.883-1.237 (with an estimated geometric mean of 1.045), for the test/reference ratio of Dopegyt and Presinol tablets, thus the two preparations proved to be bioequivalent. The relative bioavailability of Dopegyt (test preparation) and Presinol (reference preparation) calculated from the AUC0-infinity values was 116.7+/-56.7% that also confirmed bioequivalence. The results of all the applied statistical tests suggest that Dopegyt and Presinol can be considered as bioequivalent preparations.
机译:在一项为期一周的冲洗,单剂量,随机,交叉研究中,对24个健康人群中含有250 mgα-甲基多巴(AMD)的Dopegyt片剂和具有相同活性成分含量的Presinol薄膜片剂的相对生物利用度进行了研究。志愿者。由于技术上比较了两种具有完全不同的体外溶出度的完全不同的制剂(薄膜片剂和非薄膜片剂),因此将这两种制剂与第三种制剂250 mg / 50的AMD溶液(Dopegyt溶液)进行了比较。毫升浓度。在给药后24小时测量药物的血浆浓度,应用具有荧光检测的HPLC。统计评估从单个数据(AUC0-无穷大,AUC0-t,Cmax,Cmax / AUC0-无穷大,t(max))计算出的药代动力学参数。在两种片剂制剂的这些药代动力学参数中,Wilcoxon的非参数检验和四向方差分析无法在通常的a = 95%概率水平上检测到任何显着差异。对于90%概率水平的AUC0-无穷大,对于Dopegyt和Presinol片剂的测试/参比比率,置信区间为0.883-1.237(估计几何平均值为1.045),因此这两种制剂被证明具有生物等效性。由AUC0-无穷大值计算得出的Dopegyt(测试制剂)和Presinol(参比制剂)的相对生物利用度为116.7 +/- 56.7%,这也证实了生物等效性。所有应用的统计测试的结果表明多贝吉特和早老酚可以被视为生物等效制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号